- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02224313
Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research project recruits 10 healthy, premenopausal women (aged 20-40 years-old) with regular menstrual cycle with interval of 24-35 days and duration of 2-7 days and 10 healthy postmenopausal women (aged 45-60 years-old) with an intact uterus and at least 12 months but not more than 36 months of spontaneous amenorrhea.
Premenopausal women will not receive any study medication(s). Postmenopausal women will be assigned the intervention described below.
• Oral "estradiol" 1.0 mg tablet for 14 days, then oral "estradiol" 1.0 mg tablet and "progesterone" 100 mg capsule for 14 days
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- David Archer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Premenopausal and Postmenopausal women:
- Female between the ages of 20 and 40 years (premenopausal arm), OR be a female between the ages of 45 and 65 years (postmenopausal arm) willing to participate in the study, as documented by signing the informed consent form.
- Postmenopausal women with an intact uterus and at least 12 months of spontaneous amenorrhea (postmenopausal arm), OR be a premenopausal women with regular menstrual cycle with interval of 24-35 days and duration of 2-7 days (premenopausal arm).
- No oral hormone therapy for 8 weeks and transdermal or vaginal hormone therapy for 4 week prior to the study.
- Willing to use oral hormone therapy during the study period (postmenopausal women only).
- Willing to abstain from using products (other than study medication) that contain estrogen, progestin, or progesterone throughout study participation.
- Have general good health.
- Willing to refrain from sexual intercourse for 48 hours before vaginal sample collection.
- Willing to abstain from use of vaginal product 7 days before vaginal sample collection.
Exclusion Criteria:
To participate in the study, a subject must NOT
- Be allergic to estrogen or progesterone products
- Have active genital infection or inflammation based on vaginal wet preparation, power of hydrogen (pH), whiff test and potassium hydroxide (KOH) preparation 2.1 Vulvovaginal candidiasis, trichomonas vaginitis or bacterial vaginitis 2.2 Sexually transmitted diseases including herpes simplex viral infection, gonorrhea and Chlamydia
- Have a known contraindication for oral hormone therapy or allergy to use of estradiol and/or progesterone
Have used estrogen alone or estrogen/progestin for any of the following time periods:
4.1 Vaginal hormone products (ring, cream, gels) within 30 days prior to screening 4.2 Transdermal estrogen alone or estrogen/progestin products within 4 weeks prior to screening 4.3 Oral estrogen and/or progestin therapy within 8 weeks prior to screening 4.4 Progestational implants, estrogen or estrogen/progestational injectable drug therapy within 3 months prior to screening 4.5 Estrogen pellet therapy or progestational injectable drug therapy within 6 months prior to screening 4.6 Percutaneous estrogen lotions/gels within 4 weeks prior to screening
- Have used tamoxifen, raloxifene or other selective estrogen receptor modulators (SERMs) therapy within 8 weeks prior to screening
- Have used an intrauterine device (IUD) within 8 weeks prior to screening
- Have used vaginal products (pessary, tampon, tablets, douching) within 7 days prior to screening
- Have evidence of cervical, vaginal, or vulvar intraepithelial neoplasia or cancer
- Have a past or current history breast cancer, endometrial cancer or endometrial hyperplasia, hypertriglyceridemia or venous thromboembolism
- Be an immuno-compromised patient including those with human immunodeficiency viral infection, chronic glucocorticoid use or active treatment with immunosuppressive agents
- Have a history of or current evidence of thromboembolism
- Have evidence of uncontrolled Hypertension Blood pressure >140/100 mmHg
- Have confirmed Diabetes Mellitus
- Currently smoking
- For sexually active premenopausal women, should be protected against pregnancy by sterilization, condom use, abstinence, or same sex relationship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 1.Premenopausal women
No treatment
|
|
Experimental: 2.Postmenopausal women with hormones
Oral hormone therapy will be given to women in this group.
Daily dose of oral "estradiol" 1 mg will be given the first 14 days after enrollment.
Then a daily dose of oral "estradiol" 1 mg and "progesterone" 100 mg for 14 days will be given during the following 14 days.
|
one tablet of oral estradiol 1.0 mg once a day for 28 days
Other Names:
one tablet of oral progesterone 100 mg once a day for 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal Cytokines at Baseline
Time Frame: At baseline visit
|
Determine the differences in vaginal cytokines: interleukin (IL)-1β and IL-8 between premenopausal and postmenopausal women.
|
At baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal Cytokines During Follow-up
Time Frame: At 14 days and 28 days follow-up
|
Determine the changes in vaginal cytokines in postmenopausal women following treatment with estradiol then estradiol and progesterone compared to the normal menstrual cycle changes in young premenopausal women.
|
At 14 days and 28 days follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: David F Archer, MD, Eastern Virginia Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRC-VgCy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
Clinical Trials on oral estradiol 1.0 mg
-
Novo Nordisk A/SCompletedHealthy | MenopauseGermany
-
Novo Nordisk A/SCompletedHealthy | MenopauseSweden, Norway
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Novo Nordisk A/SCompletedMenopause | Menopausal Vasomotor SymptomsDenmark, United Kingdom, Sweden, Belgium, Switzerland, Germany, France, Finland, Austria, Norway
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.Completed
-
Novo Nordisk A/SCompleted
-
Grünenthal GmbHGrünenthal, S.A.Withdrawn
-
Cerevel Therapeutics, LLCRecruitingApathy in DementiaUnited States, Canada